Business
RenovoRx Reports Full Year 2021 Financial Results
LOS ALTOS, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted
About this update from Renovorx, Inc.
[{"type":"text","content":" LOS ALTOS, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the year ended December 31, 2021.\n\n“2021 was a transformative year for RenovoRx. We successfully closed on our initial public offering and listed on the NASDAQ under ‘RNXT,’” said Shaun Bagai, CEO of RenovoRx. “Importantly, despite challenges created by the COVID-19 pandemic, we maintained steady enrollment in our Phase 3 clinical trial in locally advanced pancreatic cancer. We recently achieved approximately 50% of the target enrollment under the current statistical analysis plan. One of the issues with systemic chemotherapy is the significant side effects to the entire body. RenovoRx is addressing this problem by localizing therapy to treat tumors via our proprietary RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion) therapeutic platform. Today, we have the strategy and team to build on our progress in treating pancreatic cancer with the opportunity to extend the RenovoTAMP platform to other cancers. We are challenging the bounds typically associated with treating solid tumors to improve survival and quality of life for patients undergoing chemotherapy.”\n\n2021 Operational Highlights:\n\n\nIssuance of seventh U.S. patent extending the intellectual property coverage of the RenovoTAMP therapy platform.\n\n\nClosed on IPO and listed on the Nasdaq Capital Market under the ticker symbol, “RNXT.”\n\n\nReceived new 510(k) clearance for the RenovoCath® delivery system (the device component of the Company’s initial product, RenovoGem™). RenovoRx received its initial 510(k) for the RenovoCath delivery system in 2014.\n\n\nAnnounced final data from RR2 observational registry study. Phase 1/2 trials demonstrated that prior radiation treatment, together with targeted chemotherapy delivered via RenovoTAMP, reduced the tolerability issues typically associated with systemic chemotherapy and improved survival.\n\n\n2022 Operational Highlights and Upcoming Targeted Milestones:\n\n\nBegan enrolling patients at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in ongoing TIGeR-PaC Phase 3 Clinical Trial.\n\n\nTIGeR-PaC achieved approximately 50 percent of the target enrollment under the current statistica...